Journal of translational science最新文献

{"title":"Docetaxel causes lymphatic endothelial cell apoptosis and impairs lymphatic function and gene expression in vitro","authors":"Wong Am, Baik Je, H. Park, C. Li, Shi Jy, Kataru Rp, Mehrara Bj","doi":"10.15761/jts.1000402","DOIUrl":"https://doi.org/10.15761/jts.1000402","url":null,"abstract":"Introduction: Recent studies have shown that taxanes — chemotherapeutic agents commonly used for breast cancer treatment—may increase the risk of lymphedema development in breast cancer survivors. The purpose of this study was to analyze the effects of docetaxel on lymphatic endothelial cells (LEC) and define the cellular mechanisms that may account for this clinical relationship. Methods: Human dermal LECs were cultured in vitro with varying concentrations of docetaxel and LEC viability, proliferation, migration, tubule formation and lymphatic gene expression were analyzed. Results: Docetaxel, at a concentration of 100 µM, was cytotoxic to LECs resulting in impaired proliferation. At the lower concentrations (1 and 10 µM), docetaxel impaired LEC function by decreasing LEC migration and tubule formation. The expression of lymphatic markers podoplanin, LYVE1 and FLT4, but not PROX-1 were down-regulated in LECs following high concentration of docetaxel treatment (100 µM). Conclusion: High concentration of docetaxel induces LEC death and impair LEC proliferation and lymphatic gene expression. In contrast, low concentration of docetaxel significantly impairs LEC migration and tubule formation. These adverse effects of docetaxel may therefore provide a cellular mechanism underlying the clinical observation that taxane therapy increases the risk of lymphedema development in cancer patients.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67491806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of individual placement and support (IPS) studies and results on health status of people with long-term mental disorder and competitive employment","authors":"F. R. Pulido, Nayra Caballero Estebaranz, Dácil Oramas Pérez, C. Palacín","doi":"10.15761/JTS.1000398","DOIUrl":"https://doi.org/10.15761/JTS.1000398","url":null,"abstract":"Ordinary employment, from the vulnerability-stress model, is believed to trigger relapses in people with long-term mental disorders when subjected to demanding work environments. To test the accuracy of this hypothesis, different databases between 1998 and 2019 (May) were consulted, using various key words. Randomized Clinical Trials (RCTs) that analyzed non-vocational outcomes related to symptomatology and hospitalizations in the Individual Placement and Support (IPS) strategy with severe mental disorders were specifically reviewed. A total of 383 references were reviewed, 26 were selected and 18 were included. Of the selected studies the follow-up period is between 12 months and 24 months for the most part. Samples usually range from 100-200 participants but there are studies with larger samples, one study with over 2059 participants. The most commonly used outcome is admissions and relapses, the most commonly used being days of hospitalization. The most widely used scales were on overall functioning, GAF and to measure relapse, PANNS and BPRS. Competitive employment was found not to cause relapses or hospitalisations, and long-term employment seemed to contribute to a favourable clinical evolution, although the degree of impact on the health status has yet to be proven.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67492046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Milciclib and sorafenib synergistically downregulate c-Myc to suppress tumor growth in an orthotopic murine model of human hepatocellular carcinoma","authors":"A. Jindal, Vaseem A Palejwala, M. Ciomei, A. Degrassi, G. Texidó, K. Shailubhai","doi":"10.15761/jts.1000416","DOIUrl":"https://doi.org/10.15761/jts.1000416","url":null,"abstract":"Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and a leading cause of cancer-related deaths worldwide [1,2]. Chronic liver inflammation resulting from prolonged viral hepatitis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and other metabolic disorders such as excessive alcohol consumption and exposure to aflatoxins represent major etiological factors for HCC [1-3]. These multitude of underlying mechanisms that affect disease course and patient prognosis underscores the importance of a broad-spectrum approach to target multiple mechanisms underlying HCC development and promotion [4]. Current therapies for HCC include specific tyrosine kinase inhibitors (TKIs) such as sorafenib (Nexavar®), regorafenib (Stivarga®), lenvatinib (Lenvima®) and cabozantinib (Cabometyx®) [5-9]. In addition, immunotherapies with nivolumab (Opdivo®) and pembrolizumab (Keytruda®) both inhibiting programmed cell death receptor PD-1, have also been approved as second line treatment for advanced HCC [10,11]. Although these therapies have shown significant clinical benefits for HCC patients, but the clinical response rate is still low. Thus, there is an immediate need for drugs, preferentially with different mechanisms, which could be used in suitable combinations to complement existing therapies and to improve clinical outcome without compromising safety.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67492266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trastuzumab emtansine (T-DM1) and concurrent radiotherapy for treatment of HER2-positive breast cancer: Review of literature","authors":"M. M, A. G., Sgambato A, C. G., Iannace C, Gridelli C","doi":"10.15761/jts.1000448","DOIUrl":"https://doi.org/10.15761/jts.1000448","url":null,"abstract":"","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67499496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deriving a patient de-identified clinical research database from an electronic health record system: A single center experience in determining the prognostic value of lactate, C-reactive protein, and procalcitonin in hospitalized patients","authors":"R. Mohan, P. PhillipHo, L. Dalton, F. Chan, Nguyen Hb","doi":"10.15761/jts.1000405","DOIUrl":"https://doi.org/10.15761/jts.1000405","url":null,"abstract":"Objective : In this study, we demonstrate the derivation of a de-identified research database from the electronic health records (EHR) and then use it in determining the prognostic value of biomarkers lactate, C-reactive protein (CRP), and procalcitonin in hospitalized patients. Methods : The database was created through a series of data export, transform, load, and visualization. A database glossary was completed, including 650 data elements per patient encounter without personal identifiers. Data visualization and statistical analysis tools were provided to those utilizing the database. Results : From July 2012 to August 2019, the database contained 240,759 distinct hospital encounters, with 2,682 patients meeting criteria for analysis, age 54.5±18.6 years, lactate 1.9±1.7 mmol/L, CRP 10.7±10.0 µg/mL, procalcitonin 4.0±17.5 ng/mL, and mortality 8.7%. ROC area under the curve for lactate, CRP, and procalcitonin was 0.670, 0.553, and 0.672, respectively. Lactate, CRP, and procalcitonin had odds ratio for mortality of 1.111 (1.037-1.190), 1.015 (0.991-1.031), and 0.999 (0.991-1.007), respectively. Conclusions : Our efforts provide a framework for creating EHR-derived de-identified patient data for clinical research. Our analysis of the prognostic value of lactate, CRP, and procalcitonin showed these biomarkers to be less accurate than expected, highlighting the challenges of using existing data.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67491994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological and radiological biomarkers in SARS-CoV-2 infected healthcare workers in governmental hospitals in Qatar","authors":"Rahman M U A, Prabhu Ks, Raza A, Elmi M, Mahmood N, S. Mh, Abid Fb, Dermime S, Uddin S, A. M, M. Mi","doi":"10.15761/jts.1000464","DOIUrl":"https://doi.org/10.15761/jts.1000464","url":null,"abstract":"","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"81 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67499166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19: The third wave of coronavirus infection outbreak","authors":"L. Sokolovska, A. Sultanova, M. Cistjakovs, M. Murovska","doi":"10.15761/JTS.1000389","DOIUrl":"https://doi.org/10.15761/JTS.1000389","url":null,"abstract":"The novel coronavirus SARS-CoV-2 poses a great public health crisis. As of December 2019, it has spread all over the world with cases reported in more than 100 countries and the number of infected individuals surpassing 1,000,000. On March 11 World Health Organization officially characterized the COVID-19 as a pandemic. Although genetic analysis revealed some similarities between the novel coronavirus and the causative agent of the 2002 SARS epidemic, both viruses have significant differences. Research done on SARS-CoV has greatly aided the understanding of SARS-CoV-2, as it served as a knowledge base and helped to identify the cell entry receptor and some other features of the disease, but not all of them. Several critical questions remain unanswered and specific therapeutics and vaccine candidates are lacking.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67491194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SARS-CoV-2: Endoscopy procedures at risk of airborne particles transmission","authors":"Frossard Jl, F. Negro","doi":"10.15761/jts.1000400","DOIUrl":"https://doi.org/10.15761/jts.1000400","url":null,"abstract":"SARS-CoV-2: Endoscopy procedures at risk of airborne particles transmission.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67491734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposed mechanism for anosmia during COVID-19: The role of local zinc distribution","authors":"O. Equils, K. Lekaj, Sahar Fattani, Arthur W. Wu, Gene C. Liu","doi":"10.15761/JTS.1000397","DOIUrl":"https://doi.org/10.15761/JTS.1000397","url":null,"abstract":"Received: May 19, 2020; Accepted: June 04, 2020; Published: June 08, 2020 The common cold is frequently associated with anosmia. A significant portion of COVID-19 patients has been reported to have anosmia and taste dysfunction [1]. A recent study from Germany found that among confirmed COVID-19 patients 47% had anosmia with a mean duration of anosmia of 8.9 days as well as an association with dysgeusia in 85% of cases [2].","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67491842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammation induced by very low-dose bisphenol-a can be prevented by probiotics","authors":"M. Nanayakkara, Ilaria Cimmino, C. Cerchione, V. D'Esposito, F. Oriente, R. Troncone, P. Formisano, M. Barone, R. Valentino","doi":"10.15761/jts.1000403","DOIUrl":"https://doi.org/10.15761/jts.1000403","url":null,"abstract":"Bisphenol-A (BPA) is an endocrine disruptor found in the majority of plastic components with pro-inflammatory effects on adipose tissue, the immune system and the intestine, the first tissue exposed to the effects of BPA. Humans are chronically exposed to BPA through contaminated food and beverages. The aim of this study was to investigate the effect of a very low dose of BPA (0.1 nM) on intestinal epithelial cells during differentiation, compare it with that of a low dose of BPA (1 nM), and determine the role of probiotics in preventing BPA-induced alterations in intestinal permeability and inflammation. Human colon adenocarcinoma-derived cells (Caco2 cells) were treated with 0.1 nM and 1 nM BPA in the presence of G-1 and G15, a specific GPR30 agonist and antagonist, respectively, and probiotics during differentiation, after which transepithelial electrical resistance (TEER) measurements, confocal fluorescence experiments, real-time RT-PCR and Western blot analysis were carried out. Even at a dose of 0.1 nM, BPA significantly reduced TEER in differentiated Caco2 cells. The increased permeability of the enterocyte monolayer and a reduction in Caco2 cell thickness confirmed the effects of BPA. In addition, BPA induced GPR30 expression and ERK1/2 and NF-κB phosphorylation, especially in the early phase of CaCo2 cell differentiation. However, inhibition of GPR30 by G15 reduced the effect of BPA on ERK1/2 and NF-κB phosphorylation. Interestingly, the supernatant of cells grown with the probiotic LGG could prevent the decrease in TEER, alteration of tight junctions (TJs) and induction of pNF-κB. Very low-dose BPA (0.1 nM) and low-dose BPA (1 nM) induced intestinal inflammation and altered intestinal permeability through a mechanism involving GPR30. Treatment with the probiotic LGG reversed the effects of BPA. *Correspondence to: M. Vittoria Barone, Department of Translational Medicine, Federico II University of Naples & ELFID (European Laboratory for the Investigation of Food Induced Disease), Italy, E-mail: mv.barone@unina.it","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67491959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}